logo-loader
ImmunoPrecise Antibodies Ltd

ImmunoPrecise boosts screening capability with lab equipment purchase

A second Intellicyt iQue Screener PLUS device allows scientists to reduce lead discovery time while conserving samples and reducing reagent cost

An illustration of antibodies
The equipment upgrade advances ImmunoPrecise's strategic vision, according to the company

ImmunoPrecise Antibodies Ltd (OTCMKTS:IPATF) (CVE:IPA) said Tuesday that it has acquired additional integrated laboratory equipment for high-throughput antibody screening.

The Victoria, British Columbia, biotech company said in a statement that its purchase of a second Intellicyt iQue Screener PLUS allows its scientists to reduce lead discovery time while conserving samples and reducing reagent cost.

READ: Immunoprecise Antibodies reports 2Q revenue doubled on increased capacity, European expansion

Other antibody screeners, according to the company, report on binding one target at a time, which makes the discovery process time-consuming and can require large amounts of target protein.

"The decision to acquire a second Intellicyt iQue will further support IPA's strategic vision of continued growth and expansion in providing end-to-end therapeutic antibody discovery services to a rapidly expanding list of pharma and biotech clients," said CEO Jennifer Bath in a statement.

The company operates globally to offer antibody services from target analysis to pre-clinical studies. It works out of labs in Victoria as well as in Utrecht and Oss in the Netherlands.

Shares traded at C$0.68 in Monday’s Canadian trading. They were down US$0.04 to US$0.51 on the OTC Markets.

Contact Dennis Fitzgerald at [email protected]

Quick facts: ImmunoPrecise Antibodies Ltd

Price: $0.63

Market: TSX-V
Market Cap: $42.34 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ImmunoPrecise Antibodies on an aggressive sales and business development drive

ImmunoPrecise Antibodies Ltd's (CVE:IPA) president and chief executive Jennifer Bath caught up with Proactive Investors at the Spring Investor Summit 2019 in New York City. Operating from their laboratory facilities at the Vancouver Island Technology Park in Victoria, British Columbia...

on 04/02/2019

2 min read